Want to see SE:BOUL full AI Analyst Report?
BOUL Stock Chart & Stats
kr3.71
kr0.06(1.64%)
―
--
Day’s Range― - ―
52-Week Rangekr3.09 - kr10.60
Previous CloseN/A
VolumeN/A
Average Volume (3M)39.59K
Market Cap
kr144.07M
Enterprise Valuekr331.65M
Total Cash (Recent Filing)kr18.50M
Total Debt (Recent Filing)kr222.00M
Price to Earnings (P/E)―
Beta0.52
Next Earnings
Jul 17, 2026EPS Estimate
0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.21
Shares Outstanding38,833,103
10 Day Avg. Volume77,284
30 Day Avg. Volume39,585
Financial Highlights & Ratios
PEG Ratio0.50
Price to Book (P/B)1.11
Price to Sales (P/S)0.38
P/FCF Ratio-45.13
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.82
Revenue Forecast (FY)kr499.00M
Bulls Say, Bears Say
Bulls Say
Recurring Consumables RevenueBoule's business model pairs instrument placements with consumables, reagents and service that recur over the analyzer life. That installed-base annuity creates predictable, higher-frequency revenue per instrument, supporting steady cash generation and long-term revenue resilience even if new instrument sales fluctuate.
Structurally Strong Gross MarginsA ~44% gross margin provides a durable profitability buffer versus peers, enabling reinvestment in R&D, customer support and distribution. Solid product-level margins help absorb pricing pressure or mix shifts and improve the chance of sustained operating profitability when fixed-cost leverage is restored.
Recent Positive Operating And Free Cash FlowRecent positive operating and free cash flow are a stabilizer for operations and debt service. Reliable near-term cash generation supports working capital, servicing leverage and targeted reinvestment, giving management flexibility to execute product or distribution initiatives without immediate external financing.
Bears Say
Elevated LeverageDebt above equity reduces financial flexibility and increases fixed interest obligations. Elevated leverage amplifies downside risk if revenue or margins slip, constrains capacity for M&A or capital investments, and lengthens the timeline to rebuild equity if operating performance does not consistently improve.
Stalled / Declining RevenuesA slight TTM revenue decline and stalled top-line growth undermine the installed-base growth needed to expand recurring consumables sales. Continued revenue weakness would pressure operating leverage, limit margin expansion and slow the conversion of instrument placements into long-term annuity revenue.
Volatile Cash GenerationHistoric swings in operating and free cash flow reduce predictability for capital allocation and debt repayment. This volatility raises the risk of future funding needs in adverse years, complicates multi-year investment planning, and makes sustained deleveraging and R&D funding more challenging.
Boule Diagnostics AB News
BOUL FAQ
What was Boule Diagnostics AB’s price range in the past 12 months?
Boule Diagnostics AB lowest stock price was kr3.09 and its highest was kr10.60 in the past 12 months.
What is Boule Diagnostics AB’s market cap?
Boule Diagnostics AB’s market cap is kr144.07M.
When is Boule Diagnostics AB’s upcoming earnings report date?
Boule Diagnostics AB’s upcoming earnings report date is Jul 17, 2026 which is in 15 days.
How were Boule Diagnostics AB’s earnings last quarter?
Boule Diagnostics AB released its earnings results on Apr 28, 2026. The company reported -kr0.38 earnings per share for the quarter, missing the consensus estimate of kr0.15 by -kr0.53.
Is Boule Diagnostics AB overvalued?
According to Wall Street analysts Boule Diagnostics AB’s price is currently Undervalued.
Does Boule Diagnostics AB pay dividends?
Boule Diagnostics AB does not currently pay dividends.
What is Boule Diagnostics AB’s EPS estimate?
Boule Diagnostics AB’s EPS estimate is 0.01.
How many shares outstanding does Boule Diagnostics AB have?
Boule Diagnostics AB has 38,833,103 shares outstanding.
What happened to Boule Diagnostics AB’s price movement after its last earnings report?
Boule Diagnostics AB reported an EPS of -kr0.38 in its last earnings report, missing expectations of kr0.15. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Boule Diagnostics AB?
Currently, no hedge funds are holding shares in SE:BOUL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Boule Diagnostics AB
Boule Diagnostics AB (publ) develops, manufactures, and markets instruments and consumable products for blood diagnostics in the United States of America, Asia, Eastern Europe, Latin America, Western Europe, Africa, and the Middle East. The company provides hematology analyzers, reagents, controls, and calibrators, under the Swelab, and Medonic brands; and veterinary hematology and clinical chemistry analyzer systems, as well as reagents and panels under the Exigo brand. It serves small and medium-sized hospitals, clinics, laboratories, and veterinary clinics, and other diagnostics firms. The company was founded in 1956 and is headquartered in Spånga, Sweden.